2025
SJR Q1
JCR Q2 · 3,1
2 matched articles
SCIE
Journal detail
Current Opinion in Nephrology and Hypertension
- Publisher
- Lippincott Williams and Wilkins
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
1062482114736543
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,939
- Quartile Q1
- H-Index 113
- Cites/doc 2,94
- Docs (3y) 251
- Cites (3y) 728
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 3,1
- 5Y JIF 3
- JCI 0,52
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Internal Medicine Q2
- Nephrology Q1
Areas
- Medicine
WoS categories
- Urology & Nephrology | Peripheral Vascular Diseases
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q2 | 0,939 | 3,1 | 3 | 0,52 | Q3 | 113 |
| 2024 | Q1 | Q2 | 0,982 | 2,4 | 2,8 | 0,5 | Q3 | 109 |
| 2023 | Q1 | Q2 | 0,959 | 2,3 | 2,7 | 0,58 | Q2 | 109 |
| 2022 | Q1 | Q2 | 0,901 | 3,2 | 3,2 | 0,59 | Q2 | 109 |
| 2021 | Q1 | Q2 | 0,968 | 3,4 | 3,8 | 0,58 | Q2 | 109 |
| 2020 | Q1 | Q2 | 1,158 | 2,9 | 3,7 | 0,59 | Q2 | 109 |
| 2019 | Q1 | Q2 | 1,091 | 2,5 | 3,2 | 0,6 | Q2 | 109 |
| 2018 | — | Q1 | — | 3 | 3,2 | 0,7 | Q2 | — |
| 2017 | Q1 | Q1 | 1,513 | 3,4 | 3,4 | 0,71 | Q2 | 109 |
| 2016 | Q1 | Q1 | 1,457 | 3,5 | 3,4 | — | — | 109 |
| 2015 | Q1 | Q1 | 1,66 | 3,2 | 3,3 | — | — | 109 |
| 2014 | Q1 | Q1 | 1,579 | 3,9 | 3,7 | — | — | 109 |
| 2013 | Q1 | Q1 | 1,944 | 4,2 | 3,9 | — | — | 109 |
| 2012 | Q1 | Q1 | 1,742 | 4 | 3,8 | — | — | 109 |
| 2011 | Q1 | Q1 | 1,616 | 4,3 | 3,7 | — | — | 109 |
| 2010 | Q1 | Q1 | 1,541 | 4,5 | 3,9 | — | — | 109 |
| 2009 | — | Q1 | — | 4 | 3,7 | — | — | — |
| 2008 | — | Q1 | — | 4 | 4 | — | — | — |
| 2007 | — | Q1 | — | 4,1 | 3,4 | — | — | — |
| 2006 | — | Q1 | — | 4,1 | — | — | — | — |
| 2005 | — | Q1 | — | 3,9 | — | — | — | — |
| 2004 | — | Q1 | — | 3,2 | — | — | — | — |
| 2003 | — | Q1 | — | 4 | — | — | — | — |
| 2002 | — | Q1 | — | 3,1 | — | — | — | — |
| 2001 | — | Q1 | — | 2,5 | — | — | — | — |
| 2000 | — | Q1 | — | 2,5 | — | — | — | — |
| 1999 | — | Q1 | — | 2,4 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q3 | 36/100 |
| 2025 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q3 | 38/134 |
| 2024 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q3 | 45/98 |
| 2024 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q3 | 51/133 |
| 2023 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 44/96 |
| 2023 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q3 | 51/126 |
| 2022 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 28/68 |
| 2022 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q3 | 29/88 |
| 2021 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 36/67 |
| 2021 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q3 | 34/90 |
| 2020 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 35/65 |
| 2020 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q3 | 44/89 |
| 2019 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 35/65 |
| 2019 | UROLOGY & NEPHROLOGY | SCIE | Q2 | Q3 | 33/85 |
| 2018 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 24/65 |
| 2018 | UROLOGY & NEPHROLOGY | SCIE | Q1 | Q2 | 18/80 |
| 2017 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 17/65 |
| 2017 | UROLOGY & NEPHROLOGY | SCIE | Q1 | Q2 | 13/76 |
| 2016 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 19/63 |
| 2016 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 18/77 |
| 2015 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 18/63 |
| 2015 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 17/77 |
| 2014 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 13/60 |
| 2014 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 11/78 |
| 2013 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 11/65 |
| 2013 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 8/77 |
| 2012 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 12/68 |
| 2012 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 8/73 |
| 2011 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 11/68 |
| 2011 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 9/73 |
| 2010 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 10/68 |
| 2010 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 8/69 |
| 2009 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 12/61 |
| 2009 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 9/63 |
| 2008 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 11/56 |
| 2008 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 8/57 |
| 2007 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 11/54 |
| 2007 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 7/55 |
| 2006 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 9/52 |
| 2006 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 6/55 |
| 2005 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 10/51 |
| 2005 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 5/51 |
| 2004 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 15/51 |
| 2004 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 8/52 |
| 2003 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 9/52 |
| 2003 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 4/49 |
| 2002 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 13/52 |
| 2002 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 6/47 |
| 2001 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 15/50 |
| 2001 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 8/44 |
| 2000 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 18/45 |
| 2000 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 7/43 |
| 1999 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 16/44 |
| 1999 | UROLOGY & NEPHROLOGY | SCIE | Q1 | — | 10/45 |